Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Industry: Healthcare

OFF LIST - 1968 consecutive market days: OFF LIST as of 08/11/2008 Through 11/14/2016

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Current Quote*
Last: $23.615
Change: -0.525
Book: $4.787
Volume: 272,096

As Of: 11/19 15:53 ET
*Quotes delayed by 20min.

Graphs for VNDA


3 Month Graph


6 Month Graph


1 Year Graph